• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights of People with ALS/MND and Caregivers
    • Research
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Development
      • AB Science – Masitinib
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Radicava/Edaravone
      • Neudexta
      • Riluzole/Tiglutik
  • Support for Health Professionals
    • How to Break the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Award Nomination
      • Forbes Norris Award Nomination
      • Humanitarian Award Nomination
      • Allied Health Professional Award Nomination
  • Members
    • Member Registration
    • Forgot Password

Biogen – Tofersen

Biogen – SOD1 Antisense Oligonucleotide (BIIB067 – Tofersen)

Background

Biogen partnered with Ionis Pharmaceuticals to advance a type of therapy called antisense oligonucleotides (ASOs), which are biological substances that can block the production of a specific gene/protein target. The first ASO target for ALS is superoxide dismutase 1 (SOD1); the first gene discovered to cause ALS back in 1993. A small change in the composition of the SOD1 gene leads to an abnormal SOD1 protein. Over the years, it was determined that this abnormal protein causes ALS, not by losing its normal, protective function, but by becoming toxic to motor neurons. An ASO that blocks SOD1 production was suggested as a logical treatment target.

A phase 1-2 clinical trial of tofersen (the SOD1 ASO) with 50 participants was started in 2016 at 17 sites in the United States, Europe and Canada with the goal of assessing safety, tolerability and of understanding how it acts inside the human body. The study showed that these goals were met and a secondary measure of whether there was reduced SOD1 in the cerebrospinal fluid (a biomarker of effect) was also significantly achieved. Furthermore, there was a trend towards slowing of ALS progression in three measures including functional decline, respiratory function and muscle strength. This means that the treatment seemed to be very effective at slowing the loss of these three measures, but the number of participants was too low to form conclusions with statistical certainty. Results were published here in July 2020 and based on the promising results of these first two steps, tofersen was studied for safety and efficacy in a phase 3 clinical trial called VALOR, with readout planned for 2021.

In April 2021, Biogen announced the intent to offer a first stage of early access to a subset of individuals affected by SOD1-ALS beginning with individuals who have the most rapidly progressive disease. This program began in July 2021. The second stage, aimed at providing access to the broad SOD1-ALS population would be triggered by phase 3 study results that indicate safety and efficacy, yielding no need for additional studies.

On October 17, 2021, a presentation and press release described the results of the phase 3 VALOR study indicating that while tofersen did not demonstrate statistical significance in the primary measure of disease progression as measured by the ALSFRS-R, multiple secondary and exploratory measures of motor function, respiratory function, muscle strength and quality of life suggested the potential of a positive effect. Reduction in SOD1 levels resulting in a statistically significant reduction in CSF neurofilament light chain levels (NfL) also suggest potential perseveration of neuronal health. Further analysis of the trial data by the scientific and medical community will be necessary to better understand these complex results and how they correlate to a potential for a clinically meaningful effect in people living with ALS caused by mutations in the SOD1 gene.

On June 3, 2022, additional 12-month open label extension (OLE) data was presented, demonstrating a more robust effect for all participants originally randomized to tofersen in the first six months (termed “early-start”) as compared to those on placebo (termed “delayed-start”). Reduction of target SOD1 levels was sustained in months 6-12 of the OLE and plasma NfL levels in the delayed-start group were reduced to levels of the early start group. ALSFRS-R was significantly higher in the early-start group after twelve months of OLE, as is respiratory function, muscle strength and two quality of life questionnaires. The data also indicates a trend towards stabilized or improved functions during months 6-12 in the delayed-start group, as well as effect on survival in the early-start group, but these should be interpreted with caution until longer term data is obtained.

On July 26, 2022, it was announced that the U.S. Food and Drug Administration (FDA) accepted Biogen’s New Drug Application for tofersen and granted it Priority Review with an action date of January 25, 2023. The FDA has noted that it is currently planning to hold an Advisory Committee meeting for this application, on a yet-to-be determined date. Biogen is seeking approval of tofersen under the FDA’s Accelerated Approval pathway, based on the use of neurofilament as a surrogate biomarker, indicating that they intend it to predict clinical benefit. No information is available yet about applications to other jurisdictions for regulatory approval.

Early Access Program

Since 2021, Biogen has “expanded eligibility for its ongoing early access program to all people with SOD1-ALS, in countries where such programs are permitted by local regulations and future access may be secured.” Individuals with an ALS diagnosis associated with a mutation in the SOD1 gene are eligible to receive tofersen free-of-charge provided their clinician is able to provide a prescription and demonstrated capability to deliver the treatment. Of note, Biogen is legally unable to provide financial support for the clinical delivery of tofersen so clinics would need to have the capacity to support treatment independently. It was also stated that they may revise or discontinue this program if no clear path forward is established for tofersen or if another trial is required.

Biogen has also initiated the ATLAS study in 2021 to determine if pre-symptomatic treatment of SOD1 mutation carriers may represent more optimal timing of intervention. Given that individuals with SOD1 mutations can be recognized as at-risk of developing ALS through genetic testing prior to onset of symptoms, tofersen represents a tremendous opportunity to determine if treatment in pre-symptomatic individuals could provide a more robust effect on disease progression.

Early intervention has long been considered as likely optimal in ALS/MND, though it has never been clinically tested. The ability to initiate experimental and proven treatments upstream of clinical symptom onset is a milestone that requires a biological indicator (biomarker) of underlying disease processes being triggered.

In recent years, a significant amount of work has yielded the protein called neurofilament light chain (NfL) as a potential blood biomarker to indicate that nervous system damage has occurred. While this is not specific for ALS, when combined with known, disease-causing genetic mutations, it may provide an opportunity to visualize the pre-clinical triggering of ALS/MND processes.

The ATLAS clinical trial will study approximately 150 individuals with SOD1 mutations that are typically associated with rapid disease progression. Participants will be screened monthly for NfL levels and when there is a rise in levels above a particular threshold, they will be enrolled into the portion of the study where they will be randomized to either tofersen or placebo. Any participant, upon developing clinical symptoms of ALS/MND, will be moved to an open-label portion where they will receive tofersen. This ensures that no one in the study who has been diagnosed by an ALS clinician will be treated with placebo.

The novel primary measure of evaluation will be the proportion of participants who develop clinical symptoms of ALS within one year of randomization. Given that the participants will have SOD1 mutations associated with rapid progression, if a significant number do not have clinical symptoms after one year, it would suggest that tofersen is able to delay the disease process. Participants will be treated for up to two years as part of the study.

Future Pre-symptomatic Clinical Trials

It is hoped that the ATLAS trial will pave the way for more pre-symptomatic trials in the future. Should therapies become proven as effective for other known genetic mutations, these pre-symptomatic studies may indicate the next logical step and will have learned from ATLAS in the effectiveness of using NfL as a trial initiation biomarker in practice. For cases where there is no identifiable mutation in a known ALS gene, researchers will need to identify additional biomarker(s) that can differentiate between nervous system damage indicating ALS versus that of many other conditions. As of 2021, there is nothing fitting this criterion that is close to clinical use, but a strong effort is underway in labs around the world.

_____________________________________________________________________________________

ATLAS trial design overview

Summary

Based on the available evidence, it is the opinion of the SAC that tofersen is likely to have a significant benefit for people living with ALS caused by a mutation in the SOD1 gene, particularly in those starting treatment earlier. Despite currently being under review by the FDA for approval, further data should continue to be collected and monitored to determine if this benefit is confirmed and sustained. The pre-symptomatic ATLAS trial is an important next step in the evaluation of tofersen for SOD1-ALS and represents a landmark for all future ALS trials. Biogen should continue to explore options that could provide access to people living with SOD1-ALS who stand to benefit from tofersen as indicated by detailed analysis of the data presented to date. The SAC encourages any member organization to reach out to the company directly to enquire whether any plans exist for their country or region.

 

International Alliance of ALS/MND Associations
August 2022

 


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Clinical Trial

  • AB Science – Masitinib
  • Amylyx – AMX0035
  • Biogen – Tofersen
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • Cytokinetics – Reldesemtiv
  • Kadimastem – AstroRx
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Orphazyme – Arimoclomol
  • T Regulatory Cell Therapies

  • Joy Blakeley, Diagnosed 2017 - MND Australia

    Joy Blakeley, Diagnosed 2017 – MND Australia

  • Joyce Rusinak, Forbes Norris ALS Center, USA

    Joyce Rusinak, Forbes Norris ALS Center, USA

  • Ian Roberts

    Ian Roberts

  • Chris McCauley, Diagnosed 2015 - ALS Canada

    Chris McCauley, Diagnosed 2015 – ALS Canada

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • Karl Hughes, Diagnosed 2010 - IMNDA, Ireland

    Karl Hughes, Diagnosed 2010 – IMNDA, Ireland

  • Willi Klein

    Willi Klein

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Jo Knowlton and her dog, Scotland

    Jo Knowlton and her dog, Scotland

  • Peng Yi-Wen

    Peng Yi-Wen

  • Kirsten Harley, Diagnosed 2013 - Australia

    Kirsten Harley, Diagnosed 2013 – Australia

  • Osiel Mendoza, Diagnosed 2016 - ALS Therapy Development Institute, USA

    Osiel Mendoza, Diagnosed 2016 – ALS Therapy Development Institute, USA

  • Elkin Ramiro Gaviria Muñoz, Diagnosed  December 2018

    Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

  • Liong Ting Ngu, MND Malaysia, Diagnosed 2014, Malaysia

    Liong Ting Ngu, MND Malaysia, Diagnosed 2014, Malaysia

  • Richard Clark, MND New Zealand, Diagnosed 2011, New Zealand

    Richard Clark, MND New Zealand, Diagnosed 2011, New Zealand

  • Wilfried Leusing, Diagnosed 2010 - DGM, Germany

    Wilfried Leusing, Diagnosed 2010 – DGM, Germany

  • Marcel R. Wernard, Diagnosed 2016 - ALS Patients Connected, The Netherlands

    Marcel R. Wernard, Diagnosed 2016 – ALS Patients Connected, The Netherlands

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Ann Nicol

    Ann Nicol

  • Irene McCaughey, Diagnosed 2011 - MND Australia

    Irene McCaughey, Diagnosed 2011 – MND Australia

  • Chen Chun-Chin

    Chen Chun-Chin

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Roxana Canova, Diagnosed 2012 - Asociación ELA Argentina

    Roxana Canova, Diagnosed 2012 – Asociación ELA Argentina

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Jack Buzby, USA

    Jack Buzby, USA

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015, Switzerland

  • Brian Lovell, Diagnosed 2011 - MND Australia

    Brian Lovell, Diagnosed 2011 – MND Australia

  • Shay Rishoni, Diagnosed 2011 - Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 – Prize4Life, Israel

  • Frank "Papa" Taylor

    Frank “Papa” Taylor

  • Christian Bär, Germany

    Christian Bär, Germany

  • England-Lee-Millard, UK

    England-Lee-Millard, UK

  • Lachlan Terry, MND Australia, Diagnosed 2015, Australia

    Lachlan Terry, MND Australia, Diagnosed 2015, Australia

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • David Bishop

    David Bishop

  • Roy

    Roy
    roy

  • Ali Var, Turkey

    Ali Var, Turkey

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • UK-Mahmood-Anwar

    UK-Mahmood-Anwar

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • David Watson, MND Scotland, Diagnosed 2018, Scotland

    David Watson, MND Scotland, Diagnosed 2018, Scotland

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

    Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

  • Juvenal Bayona Romero

    Juvenal Bayona Romero

  • Duncan Bayly - MND Australia

    Duncan Bayly – MND Australia

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Erwin Coppejans, Diagnosed 2007 - ALS Liga België, Belgium

    Erwin Coppejans, Diagnosed 2007 – ALS Liga België, Belgium

Learn more about the March of Faces

Latest Tweets

  • Just now

Subscribe to our Bi-Monthly Newsletter

Fill out the form below to subscribe to the Alliance’s bi-monthly newsletter, packed with updates from members associations from around the world!

Footer

Keep in touch

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2023 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login